...here has been a lack of good evidence for the routine use of neuroprotective agents in the chemotherapy regimen, such as vitamin E, amifostine, amitriptyline, dimensa, gabapentin, glutamine and lamotrigine.[35] There are ongoing Phase II/III trials evaluating specific agents; however, at this time, the American Society of Clinical Oncology does not support their routine use.[34–36]
The treatment of neuropathic pain has several options, but again their use has not been validated by large, randomized controlled trials.
In small numbers of patients gabapentin 400 mg three-times daily and amitriptyline 10–50 mg have been shown to provide relief in severe neuropathic pain patients.[33,34]
Prednisone doses of 10 mg twice a day beginning 24 h after therapy for 5 days has demonstrated some improvement in chemotherapy-associated neuropathy.[33] A discussion with the patient on the lack of good data to support the use of such agents should occur prior to any trial of therapy.....
The treatment of neuropathic pain has several options, but again their use has not been validated by large, randomized controlled trials.
In small numbers of patients gabapentin 400 mg three-times daily and amitriptyline 10–50 mg have been shown to provide relief in severe neuropathic pain patients.[33,34]
Prednisone doses of 10 mg twice a day beginning 24 h after therapy for 5 days has demonstrated some improvement in chemotherapy-associated neuropathy.[33] A discussion with the patient on the lack of good data to support the use of such agents should occur prior to any trial of therapy.....
Žádné komentáře:
Okomentovat
Poznámka: Komentáře mohou přidávat pouze členové tohoto blogu.